Increased risk of skin cancer for psoriasis patients given ciclosporin

September 27, 2001

N.B. Please note that if you are outside North America the embargo for Lancet press material is 0001 hours UK time Friday 28th September 2001.

The risk of squamous cell cancer of the skin is increased in patients treated for psoriasis with ciclosporin in addition to photochemotherapy, conclude authors of a study in this week's issue of THE LANCET.

Immunosuppressive treatments such as ciclosporin have been associated with an increased risk of skin cancer, although most previous research has focused on patients who have had organ transplants. In the early 1970s, a new treatment for the severe skin condition psoriasis was introduced-combination of the light-sensitive drug psoralen and exposure to ultraviolet-A radiation (puva); immunosupressive drugs including ciclosporin and methotrexate are used to treat severe psoriasis cases.

Isabelle Marcil and Robert Stern from Beth Israel Deaconess Medical Center, Boston, USA, aimed to assess the risk of skin cancer in patients taking ciclosporin who had been exposed to PUVA and other treatments for severe psoriasis. The frequency of squamous-cell skin cancer for 28 patients (who had previously taken part in the PUVA study) and who were on ciclosporin was compared before and after their first use of ciclosporin. The investigators also analysed the entire PUVA study population (1380 patients) to assess the relation between ciclosporin use and frequency of squamous-cell cancer.

In the 5 years before first ciclosporin use, six of 28 (21%) ciclosporin users developed a total of 20 squamous cell cancers. After ciclosporin use (average follow-up 6 years), 13 (46%) developed a total of 169 squamous-cell carcinomas. After adjustment for amount of exposure to PUVA and methotrexate, incidence of tumours was seven times higher after first ciclosporin use than in the previous 5 years. Any use of ciclosporin was associated with a three-fold increase in risk of squamous-cell cancer, and use for at least 3 months was associated with a nearly four-fold increase. Patients were at substantially greater risk with 3 months or longer use of ciclosporin than with exposure to at least 200 PUVA treatments. Long-term use of methotrexate was associated with lower risk than either any ciclosporin or high-dose PUVA use

Robert Stern comments: "New immunomodulatory therapies hold great promise for improving the treatment of severe psoriasis. However, the great increase in skin cancer risk we have documented in patients with severe psoriasis treated with the first immunomodulatory therapy for this disease strongly argues that careful assessment of the long-term safety of new immunologically based treatments for psoriasis is needed."
-end-
Contact: Jerry Berger, Director of Media Relations, Beth Israel Deaconess Medical Center, I Deaconess Road, W/PL5, Boston, MA 02215, USA; T) 1-617-632-8062; F) 1-617-632-8092; E) jberger@caregroup.harvard.edu

Lancet

Related Skin Cancer Articles from Brightsurf:

Increasing the effectiveness of immunotherapy against skin cancer
Researchers at the University of Bern have discovered a mechanism in the body's own immune system which is responsible for the maturation and activation of immune cells.

New electronic skin can react to pain like human skin
New pain-sensing prototype mimics the body's near-instant feedback response and reacts to painful sensations with the same lighting speed that nerve signals travel to the brain.

Studying how skin cancer starts
New research by Ortiz-Rodríguez and mentor Carlos Crespo, a professor and lead researcher in the The Crespo Group lab, reveals for perhaps the first time how quickly certain pre-cancerous lesions can form on the DNA of our skin when exposed to sunlight.

Skin-to-skin 'kangaroo care' shows important benefits for premature babies
A world-first study led by Monash University has demonstrated significant benefits to a premature baby's heart and brain function when held by the parent in skin-to-skin contact.

Mother/infant skin-to-skin touch boosts baby's brain development and function
As the world prioritizes social distancing due to COVID-19, research shows that extended use of Kangaroo Care, a skin-to-skin, chest-to-chest method of caring for a baby, can positively benefit full-term infants and their mothers, with important implications for post-partum depression.

IU researcher makes skin cancer discovery
An Indiana University cancer researcher has identified eight new genomic regions that increase a person's risk for skin cancer.

Skin-to-skin contact do not improve interaction between mother and preterm infant
Following a premature birth it is important that the parents and the infant quickly establish a good relationship.

Research reveals potential dangers during skin-to-skin contact for mother and baby following cesarean section birth
Research in the latest edition of the European Journal of Anaesthesiology (the official journal of the European Society of Anaesthesiology) reports the potential dangers of allowing skin-to-skin contact for mother and baby in the operating room, following a cesarean section birth.

Helping skin cells differentiate could be key to treating common skin cancer
A new study from Penn researchers has identified the key regulator that controls how the skin replaces itself and which can determine if cells turn into cancer.

Protein linked to aggressive skin cancer
Almost 300,000 people worldwide develop malignant melanoma each year. The disease is the most serious form of skin cancer and the number of cases reported annually is increasing, making skin cancer one of Sweden's most common forms of cancer.

Read More: Skin Cancer News and Skin Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.